Cancer Trials Show One Year on Roche's Herceptin is Best
Published: Oct 01, 2012
- These data showed that there was no difference in the time women lived without their disease returning (disease-free survival) when they received Herceptin for two years versus one year, a secondary endpoint of the study.
- After a median follow-up of eight years, the improvements in disease-free survival and overall survival for women who received Herceptin for one year remained statistically significant compared to women who underwent observation alone.
- There were no new safety findings in the study
-Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; firstname.lastname@example.org